cisapride has been researched along with Ventricular Fibrillation in 2 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 7.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "The FDA analyzed reports of patients who developed QT prolongation, torsades de pointes, and ventricular arrhythmia in association with the use of cisapride to assess probable etiology and risk factors." | 7.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| "To evaluate the risk of serious ventricular arrhythmia (SVA) with cisapride use in the United States." | 3.71 | Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. ( Cali, C; Enger, C; Walker, AM, 2002) |
| "The FDA analyzed reports of patients who developed QT prolongation, torsades de pointes, and ventricular arrhythmia in association with the use of cisapride to assess probable etiology and risk factors." | 3.71 | Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. ( Corken, A; Gallo-Torres, H; Rodriguez, EM; Talarico, L; Wysowski, DK, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Enger, C | 1 |
| Cali, C | 1 |
| Walker, AM | 1 |
| Wysowski, DK | 1 |
| Corken, A | 1 |
| Gallo-Torres, H | 1 |
| Talarico, L | 1 |
| Rodriguez, EM | 1 |
2 other studies available for cisapride and Ventricular Fibrillation
| Article | Year |
|---|---|
Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States.
Topics: Adolescent; Adult; Age Distribution; Age Factors; Arrhythmias, Cardiac; Child; Child, Preschool; Cis | 2002 |
Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Cisapride; Contraindications; Drug an | 2001 |